<SEC-DOCUMENT>0001193125-24-030359.txt : 20240315
<SEC-HEADER>0001193125-24-030359.hdr.sgml : 20240315
<ACCEPTANCE-DATETIME>20240209172750
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-24-030359
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Graphite Bio, Inc.
		CENTRAL INDEX KEY:			0001815776
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				844867570
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD, SUITE 120
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 484-0886

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD, SUITE 120
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Integral Medicines, Inc.
		DATE OF NAME CHANGE:	20200622
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">


<IMG SRC="g548341g92i22.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Goodwin Procter</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The&nbsp;New&nbsp;York&nbsp;Times&nbsp;Building</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">620 Eighth Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL">New York, NY 10018</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>VIA EDGAR </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;9, 2024 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States Securities and Exchange
Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Life
Sciences </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549-3628
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Doris Stacey Gama, Jason Drory, Eric Atallah and Lynn Dicker </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Graphite Bio, Inc. </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>&#8194;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment No.&nbsp;2 to Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT>
</B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>&#8194;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Filed February&nbsp;5, 2023 </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>&#8194;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>File <FONT STYLE="white-space:nowrap">No.&nbsp;333-275919</FONT> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of Graphite Bio, Inc. (the
&#147;<U>Company</U>&#148;), we are submitting this letter to the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) via EDGAR in&nbsp;response to the comment letter from the staff of the SEC (the &#147;<U>Staff</U>&#148;), dated
February&nbsp;9, 2024 (the &#147;<U>Comment Letter</U>&#148;), pertaining to the Company&#146;s above-referenced Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (the &#147;<U>Registration Statement</U>&#148;). In
connection with such responses, the Company is concurrently filing Amendment No.&nbsp;3 to the Registration Statement (the &#147;<U>Amended Registration Statement</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For your convenience, the Staff&#146;s comments are summarized in this letter, and each comment is followed by the applicable responses on behalf of the
Company. Unless otherwise indicated, page references in the responses correspond to the page numbers in the Amended Registration Statement. Capitalized terms used in this letter but otherwise not defined herein shall have the meanings set forth in
the Amended Registration Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Amendment No.&nbsp;2 to Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> filed
February&nbsp;5, 2024 </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Litigation Related to the Merger, page 23 </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Please provide the disclosures required by Item 103 of Regulation
<FONT STYLE="white-space:nowrap">S-K,</FONT> including, for example only, the relief sought. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: The
Company respectfully acknowledges the Staff&#146;s comment and advises the Staff that it has revised the disclosure on pages&nbsp;31 and 310 of the Amended Registration Statement in response to the Staff&#146;s comment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>***** </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Life Sciences </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;9, 2024 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <P STYLE="font-size:14pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please contact the undersigned at (617) <FONT STYLE="white-space:nowrap">570-1861</FONT> or via email at
agoodman@goodwinlaw.com if you have any questions with respect to the foregoing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Andrew H. Goodman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#8195; Andrew H. Goodman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#8195; Goodwin Procter LLP</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kimberlee C. Drapkin, <I>Graphite Bio, Inc. </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Maggie L. Wong, <I>Goodwin Procter LLP</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Shoaib Ghias, <I>Goodwin Procter LLP</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Tevia K. Pollard, <I>Goodwin Procter LLP</I> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g548341g92i22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g548341g92i22.jpg
M_]C_X  02D9)1@ ! 0$ ;P!O  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   1$E$2
M  0    !   1$@       8:@  "QC__; $, " 8&!P8%" <'!PD)" H,% T,
M"PL,&1(3#Q0=&A\>'1H<'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T
M,O_; $,!"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_  !$( #D W@,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M1QD*KMLSSL3@:M#5ZKN;611D4E%==SC%R*,BDHHN N11D4E%%P%R*,BDHHN
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,,4M%%@$Q2T44 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
